Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:NRIX 8 December 2025 - 15 December 2025

Cathie Wood Sells $40M in Tesla, Keeps Cutting Iridium, and Adds Nurix: What ARK Invest’s Latest Trades Signal on Dec. 15, 2025

Cathie Wood Sells $40M in Tesla, Keeps Cutting Iridium, and Adds Nurix: What ARK Invest’s Latest Trades Signal on Dec. 15, 2025

ARK Invest sold nearly 88,000 Tesla shares worth about $39.3 million across its ARKK and ARKW funds on December 12. The firm also trimmed positions in Iridium Communications and added to biotech firm Nurix Therapeutics, while increasing stakes in Robinhood and Block. The moves come as markets remain volatile after a tech-led pullback and ahead of major central bank decisions.
15 December 2025
······
Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Dyne Therapeutics shares fell 16.9% to $18.44 after announcing a $300 million stock offering. SLM Corp dropped 15%, Kontoor Brands slid 9.5%, and Waystar Holding lost 8.4%. Major indexes were little changed as investors awaited the Federal Reserve’s interest-rate decision. The U.S. 10-year Treasury yield hovered near 4.19%.
10 December 2025
···········
Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics shares jumped about 20% to $21.70 intraday on December 8, 2025, after new Phase 1 data for its BTK degrader bexobrutideg (NX-5948) in blood cancers was presented at the ASH Annual Meeting. The company reported an 83% response rate in relapsed/refractory CLL/SLL patients and scheduled a webcast for the evening. Volume was well above normal, with shares trading near a 52-week high.
8 December 2025
··

Stock Market Today

  • Genuine Parts (GPC) Shares Decline Deepens, DCF Model Suggests Undervaluation
    March 20, 2026, 4:45 AM EDT. Genuine Parts (GPC) stock has fallen 7.4% last week and 21.2% over the past month, extending a year-to-date decline of 20.1%. The three-year loss nears 29.8%, with five-year returns down 2.7%. Despite these price drops, a Discounted Cash Flow (DCF) analysis estimates intrinsic value at $165.24 per share, about 40% above the current $99.09 market price, signaling potential undervaluation. The DCF model projects substantial free cash flow growth by 2035, supporting this view. Investors face a critical decision: whether recent price moves reflect Genuine Parts' fundamentals or market sentiment is overly pessimistic. Additional valuation metrics, including price-to-sales multiples, are considered for a holistic assessment.
Go toTop